ALK and cancer: To date, only about two‐thirds of the kinome has been covered, and more substantial inferences could be made with further population of resources (such as PhosphoSitePlus), especially when the latter also cover cancer‐associated aberrations such as fusion gene products BCR‐ABL and EML4‐ALK (Medves & Demoulin, 2012; Lee et al, 2017).